Guardant Health (GH) Q3 2026 Earnings
GAAP net loss includes $66.3 million of stock-based compensation and related payroll tax expense and $19.0 million of 'Other' items (e.g., contingent consideration and non-recurring legal expenses), both excluded from non-GAAP net loss; GAAP net loss per share was $0.93
How Did GH Stock React to Q3 2026 Earnings?
Did GH Beat Earnings? Q3 2026 Results
Yes. Guardant Health reported Q3 2026 earnings of $-0.29 a share on Nov 5, 2026, beating the $-0.31 consensus estimate by 7.8%. Revenue was $361.0M against a $350.6M estimate.
Guardant Health delivered a strong third quarter of fiscal 2026, beating analyst expectations on both the top and bottom lines as accelerating adoption of its Shield colorectal cancer screening test drove revenue 36.1% higher year over year to $360.98 million, ahead of the $350.64 million consensus. The adjusted loss per share of $0.29 came in 7.76% better than the $0.31 estimate, with the non-GAAP net loss narrowing to $38.80 million from $48.30 million a year earlier. The standout driver was the Screening segment, where revenue surged 180% to $67.60 million as Shield test volume reached 83,000, more than tripling from 24,000 a year ago; commercial coverage now extends to more than 80% of eligible lives, a figure set to grow further with recent policy expansions covering roughly 100 million lives. Oncology also contributed meaningfully, with revenue up 25% to $231.30 million on a 58% jump in test volume. Management raised its full-year 2026 revenue outlook to $1.36 billion to $1.37 billion, reflecting 38% to 40% growth, though it simultaneously widened free cash flow burn guidance to $205 million to $220 million, underscoring continued heavy investment in Shield commercialization.
- Oncology test volume up 58% to 117,000 tests
- Shield test volume up 246% to 83,000 tests
- Non-GAAP gross margin improved to 67% from 66%
- Biopharma & Data revenue growth of 8%
“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma.”
Guardant Health CEO, on the earnings call
What Is Guardant Health's Outlook?
Guardant raised its full-year 2026 outlook: - **Revenue:** $1.36–$1.37 billion (38%–40% growth vs. 2025), up from $1.34–$1.36 billion. - **Oncology:** revenue growth of approximately 30%, with volume growth now over 50%. - **Biopharma & Data:** revenue growth in the low double-digit range. - **Screening:** revenue now $233–$238 million on 285,000–290,000 Shield tests, up from $218–$230 million and 270,000–285,000 tests. - **Gross margin:** non-GAAP gross margin now 65%, vs. prior 64%–65%. - **Operating expenses:** non-GAAP operating expenses of $1.105–$1.125 billion, up from $1.080–$1.100 billion. - **Free cash flow:** burn now expected at $205–$220 million, vs. prior $195–$205 million.
GH YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $361.0M | $265.2M | +36.1% |
| Gross Profit | $236.2M | $171.6M | +37.6% |
| Operating Income | −$132.8M | −$201.5M | −34.1% |
| Net Income | −$124.4M | −$188.8M | −34.1% |
GH Revenue by Segment
When Does Guardant Health Report Next?
Figures from SEC filings and company reports. Not investment advice.